Key Segmentation:
By Component
-
Software & Platforms
-
Services
By Technology
-
Machine Learning/Deep Learning
-
Natural Language Processing (NLP)
-
Knowledge Graphs & Network-Based AI
-
Generative AI & Large Language Models (LLMs)
By Application
-
Oncology
-
Neurology
-
Cardiology
-
Infectious Diseases
-
Rare & Orphan Diseases
-
Other
By End Use
-
Pharmaceutical & Biotechnology Companies
-
Academic & Research Institutes
-
Contract Research Organizations (CROs)
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Technology X Application)
-
Competitive Product/Platform Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players in the AI Drug Repurposing Market include Insilico Medicine, BenevolentAI plc, Recursion Pharmaceuticals Inc., Atomwise Inc., Healx Ltd., Innophore GmbH, Owkin Inc., among others.
Key opportunities include expansion into rare and orphan diseases, infectious diseases, antimicrobial resistance research, multi-omics integration, and generative AI-based drug discovery.
The market is driven by rising demand for faster, cost-effective drug development, growing prevalence of chronic and rare diseases, and continued advancement of generative AI and machine learning technologies.
The Oncology segment dominated the AI Drug Repurposing Market in 2025, accounting for approximately 34.50% market share.
The North America region dominated the AI Drug Repurposing Market in 2025 with a 54.20% market share, driven by a dense concentration of AI-native drug discovery companies and strong pharmaceutical R&D investment.
The Asia Pacific AI Drug Repurposing Market is the fastest-growing region, projected to expand at a CAGR of 25.60% from 2026 to 2035.